Investment
Features
FeesSafety
Academy
More
Pluang+

Streamex Corp. announces October 2026 gold yield dividend for GLDY token holders.

Company Fundamentals
19 Oct 2026
GlobeNewsWire
View Source
Bullish
Streamex Corp. announces October 2026 gold yield dividend for GLDY token holders.

Streamex Corp. declared its seventh monthly yield distribution for GLDY, a gold-backed token, to be paid on October 19, 2026. The yield covers September 2026 and is generated through an institutional gold leasing program, offering an annualized yield of 3.735%. GLDY holders will receive additional GLDY tokens equivalent to 0.003070 ounces of gold per token. This distribution reflects Streamex's ongoing commitment to transparency and yield generation through tokenized commodity assets.

Streamex Corp.'s September 2026 yield dividend for GLDY provides context for market activity on Pluang as of Oct 20, 2026 03:01 WIB. Among 150 US stocks priced on Pluang, 63 advanced while 86 declined. Notably, COIN fell 5.91% with a strong 82% buy order activity and a typical hold time of 79 days, contrasting with UMC's 5.90% drop and more balanced sell/buy split, and JBLU's 5.71% decline but 100% buy order activity and shorter hold time of 44 days.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
30 minutes ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
30 minutes ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
1 hour ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
2 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App